AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results